Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.00
-0.5%
$5.13
$2.81
$485.37
$2.28M5.58608,470 shs17,992 shs
CORV
Correvio Pharma
$0.42
$0.41
$0.21
$2.79
$27.80M0.085.35 million shsN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
$7.37
$1.60
$6.28
$1.08M0.84180,228 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.43
-0.2%
$0.36
$0.22
$3.64
$17.86M-0.413.13 million shs25,801 shs
VIVUS, Inc. stock logo
VVUS
VIVUS
$0.37
$0.44
$4.75
$7.33M-0.841.44 million shs2.03 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-0.99%-0.33%-35.55%-85.10%-99.96%
CORV
Correvio Pharma
0.00%0.00%0.00%0.00%0.00%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+1.34%+5.86%+22.84%+39.32%-87.61%
VIVUS, Inc. stock logo
VVUS
VIVUS
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.1832 of 5 stars
3.53.00.00.00.60.01.3
CORV
Correvio Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.4938 of 5 stars
0.05.00.00.00.00.00.6
VIVUS, Inc. stock logo
VVUS
VIVUS
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.007,313,422.54% Upside
CORV
Correvio Pharma
0.00
N/AN/AN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A
VIVUS, Inc. stock logo
VVUS
VIVUS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.73N/AN/A$65.21 per share0.05
CORV
Correvio Pharma
$32.63M0.85N/AN/A($0.02) per share-21.00
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/A$3.86 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.85M3.05N/AN/A$0.25 per share1.72
VIVUS, Inc. stock logo
VVUS
VIVUS
$69.76M0.00N/AN/A($6.50) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)
CORV
Correvio Pharma
-$35.18M-$0.79N/AN/A-107.81%-2,128.82%-58.56%N/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
-$13.23MN/A0.00N/AN/AN/A-75.46%-71.18%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)
VIVUS, Inc. stock logo
VVUS
VIVUS
-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/A

Latest APVO, PRPH, CORV, VVUS, and OHRP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
CORV
Correvio Pharma
N/AN/AN/AN/AN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
VIVUS, Inc. stock logo
VVUS
VIVUS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
CORV
Correvio Pharma
22.54
1.07
0.95
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/A
3.73
3.73
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98
VIVUS, Inc. stock logo
VVUS
VIVUS
N/A
0.43
0.28

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
CORV
Correvio Pharma
7.30%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
10.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
VIVUS, Inc. stock logo
VVUS
VIVUS
7.32%

Insider Ownership

CompanyInsider Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.01%
CORV
Correvio Pharma
N/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
12.50%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
VIVUS, Inc. stock logo
VVUS
VIVUS
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000756,000Not Optionable
CORV
Correvio Pharma
13366.19 millionN/AOptionable
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
32.83 millionN/ANot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable
VIVUS, Inc. stock logo
VVUS
VIVUS
5717.87 millionN/AOptionable

Recent News About These Companies

VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS Shares Significant Regulatory Update on QSYMIA®
VIVUS Announces Label Update for QSYMIA®
VIVUS Provides Update on Pipeline and Program Milestones

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$3.00 -0.02 (-0.50%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Correvio Pharma NASDAQ:CORV

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

OHR Pharmaceutical stock logo

OHR Pharmaceutical NASDAQ:OHRP

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.43 0.00 (-0.19%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

VIVUS stock logo

VIVUS NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.